In an expanded phase II study of olaparib for MBC with GPVs in HR-related genes, no response was observed in BC patients with ATM or CHEK2 GPVs alone, although the robustness of the results was limited due to the small sample size [109]. This evidence concerns the gene CHEK2 and breast cancer.